Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Inyx Inc. Stories

2004-11-30 09:00:10

NEW YORK, Nov. 30 /PRNewswire-FirstCall/ -- Inyx, Inc. (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company focused on aerosol drug delivery technologies and products, reported today positive results from a two-year stability study for a non-ozone-depleting hydrofluoroalkane (HFA) propelled "salbutamol" metered dose inhaler (MDI) for treating asthma and other respiratory conditions utilizing Inyx's patented lipid-binding technology for enhancing the delivery of inhalation-therapy...